应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IBB 生物科技指数ETF-iShares Nasdaq
盘前交易 07-09 09:20:21 EDT
196.34
-1.89
-0.95%
盘前
197.47
+1.13
+0.57%
09:17 EDT
最高
197.81
最低
194.40
成交量
196.19万
今开
196.94
昨收
198.23
日振幅
1.72%
总市值
95.81亿
流通市值
95.81亿
总股本
4,880万
成交额
3.84亿
换手率
4.02%
流通股本
4,880万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
智通财经 · 07-08 20:01
大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
智通财经 · 07-08 19:40
大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
复宏汉霖(02696):西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌(mCRC)患者中的1期临床研究于中国境内完成首例患者给药
智通财经 · 07-08 17:27
复宏汉霖(02696):西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌(mCRC)患者中的1期临床研究于中国境内完成首例患者给药
RBC Capital上调福泰制药目标价至570美元
格隆汇 · 07-08 16:24
RBC Capital上调福泰制药目标价至570美元
(活力中国调研行)上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力
中国新闻网 · 07-08 11:56
(活力中国调研行)上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力
Vera Therapeutics股价飙升:肾病新药获FDA批准
投资观察 · 07-08 02:47
Vera Therapeutics股价飙升:肾病新药获FDA批准
翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式
智通财经 · 07-07 18:57
翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
智通财经 · 07-07 08:35
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费
美股速递 · 07-07 05:22
SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费
生物制药公司Crinetics盘后涨超100%福泰制药将以85美元/股收购公司。
智通财经 · 07-07 04:09
生物制药公司Crinetics盘后涨超100%福泰制药将以85美元/股收购公司。
Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入
美股速递 · 07-07 04:07
Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入
Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持
美股速递 · 07-07 04:06
Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持
福泰制药就囊性纤维化疗法Alyftrek与泛加拿大药品联盟签署意向书
美股速递 · 07-06 22:25
福泰制药就囊性纤维化疗法Alyftrek与泛加拿大药品联盟签署意向书
再生元制药公司预计2026年第二季度GAAP及非GAAP每股摊薄收益将减少1美元——SEC文件披露
美股速递 · 07-06
再生元制药公司预计2026年第二季度GAAP及非GAAP每股摊薄收益将减少1美元——SEC文件披露
礼来与再生元制药公司入选FDA首批加速新生产设施审查计划
投资观察 · 07-06
礼来与再生元制药公司入选FDA首批加速新生产设施审查计划
ETF日报|2倍做空闪迪ETF 涨逾28%;三倍做空半导体ETF 涨近17%;成长承压、贵金属走强
ETF追踪 · 07-03
ETF日报|2倍做空闪迪ETF 涨逾28%;三倍做空半导体ETF 涨近17%;成长承压、贵金属走强
ETF日报|2倍做多Firefly Aerospace ETF涨超36%;2倍做多Arm ETF涨超32%;成长科技与贵金属双强
ETF追踪 · 03-26
ETF日报|2倍做多Firefly Aerospace ETF涨超36%;2倍做多Arm ETF涨超32%;成长科技与贵金属双强
ETF日报|2倍做多Hims & Hers ETF涨超81%;三倍做多半导体ETF涨超11%;成长风格领跑
老虎资讯综合 · 03-10
ETF日报|2倍做多Hims & Hers ETF涨超81%;三倍做多半导体ETF涨超11%;成长风格领跑
ETF追踪 | 生物科技ETF:在经济不确定中把握增长和防御机会
ETF小帮手 · 2024-10-30
ETF追踪 | 生物科技ETF:在经济不确定中把握增长和防御机会
加载更多
公司概况
公司名称:
生物科技指数ETF-iShares Nasdaq
所属市场:
NASDAQ
上市日期:
--
主营业务:
安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。 风险提示:标的成分和权重,有可能随着时间的迁移而发生变化。
发行价格:
--
{"stockData":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":196.34,"timestamp":1783540800000,"preClose":198.23,"halted":0,"volume":1961898,"hourTrading":{"tag":"盘前","latestPrice":197.465,"preClose":196.34,"latestTime":"09:17 EDT","volume":1538,"amount":302659.42108,"timestamp":1783603024340,"change":1.125,"changeRate":0.00573,"amplitude":0.01889},"delay":0,"changeRate":-0.009534379256419243,"floatShares":48800000,"shares":48800000,"eps":6.311863,"marketStatus":"盘前交易","change":-1.89,"latestTime":"07-09 09:20:21 EDT","open":196.94,"high":197.805,"low":194.4,"amount":384475662.28944004,"amplitude":0.017177,"askPrice":197.49,"askSize":149,"bidPrice":197,"bidSize":30,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783603800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":196.34,"sharesOutstanding":50050000,"nav":198.323956,"aum":9588963272.6,"dividendRate":0.002078,"bidAskSpread":0.000285,"preHourTrading":{"tag":"盘前","latestPrice":197.465,"preClose":196.34,"latestTime":"09:17 EDT","volume":1538,"amount":302659.42108,"timestamp":1783603024340,"change":1.125,"changeRate":0.00573,"amplitude":0.01889},"postHourTrading":{"tag":"盘后","latestPrice":195.9032,"preClose":196.34,"latestTime":"19:32 EDT","volume":13486,"amount":2644883.6169,"timestamp":1783553535490,"change":-0.4368,"changeRate":-0.002225,"amplitude":0.003565},"volumeRatio":0.9817927526376182,"impliedVol":0.241,"impliedVolPercentile":0.652},"requestUrl":"/m/hq/s/IBB","defaultTab":"news","newsList":[{"id":"2649299398","title":"大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299398","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649299398?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512080,"startTime":"0","endTime":"0","summary":"摩根士丹利发布研报,对福泰制药以100亿美元收购Crinetics的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物,补齐公司管线布局。根据公告,每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。值得注意的是,摩根士丹利担任福泰制药的财务顾问,协助该公司达成收购Crinetics的协议。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464871.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1585245621.USD","LU0823416689.USD","IE0009355771.USD","LU2133065610.SGD","LU0210528500.USD","LU0109394709.USD","IAI","LU0267386448.USD","KBWB","LU1720051108.HKD","LU0432979614.USD","LU2362541273.HKD","LU2236285917.USD","LU1791710400.SGD","IBB","LU0058720904.USD","IE00BZ9MQY76.HKD","LU2456880835.USD","PBE","LU1674673691.USD","IDNA","IE0002141913.USD","SG9999001176.USD","LU0528227936.USD","IE00B19Z3581.USD","LU1732799900.SGD","IE0002270589.USD","BBH","BK4139","LU0053666078.USD","LU2111349929.HKD","LU2237438978.USD","LU0882574139.USD","LU2089284900.SGD","IBBQ","LU0390134368.USD","BK4588","BK4533","LU0079474960.USD","LU1363072403.SGD","LU1244550221.USD","BK4581","BIB","LU2487616109.SGD","LU0098860793.USD","VRTX","IE00B19Z9P08.USD","LU2362540622.SGD","LU1720051017.SGD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939579","title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939579","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649939579?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:40","pubTimestamp":1783510856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1430594728.SGD","LU2347655156.SGD","LU1074936037.SGD","SG9999001176.USD","LU0053666078.USD","LU1244550221.USD","LU0795875086.SGD","LU1585245621.USD","PBE","LU2237438978.USD","SG9999013999.USD","IE00B19Z9Z06.USD","IDNA","LU1548497426.USD","LU0314104364.USD","LU0061475181.USD","BK4567","LU0882574139.USD","IBB","BK4127","LU2362540622.SGD","IE00B19Z3581.USD","LU1720051017.SGD","LU0795875169.SGD","BK4139","KBWB","SG9999001176.SGD","LU1244550577.SGD","LU0006306889.USD","LU0823416689.USD","LU1674673428.USD","BBH","IE00B19Z3B42.SGD","LU0417517546.SGD","LU2089283258.USD","LU0079474960.USD","LU2271345857.HKD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU2133065610.SGD","BIB","IBBQ","VRTX","LU2487616109.SGD","LU2417539215.USD","LU2462157665.USD","IAI","LU2362541273.HKD","LU1668664300.SGD","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964779","title":"复宏汉霖(02696):西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌(mCRC)患者中的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964779","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649964779?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:27","pubTimestamp":1783502848,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖 发布公告,近日,本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌患者中的1期临床研究于中国境内完成首例患者给药。本研究是一项在KRAS/NRAS野生型且BRAF V600E无突变的转移性结直肠癌参与者中,比较HLX05-N与美国及欧盟来源Erbitux联合化疗 治疗的多中心、随机、双盲、平行对照1期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320264.USD","LU1992135472.HKD","LU1992135399.USD","LU2272731782.SGD","BK4585","HK0000306701.USD","XPH","LU2473716301.USD","HK0000320223.HKD","02696","LU2322448957.HKD","IE00B5TLWC47.USD","BK1161","LU2272731600.USD","IBB","HK0000165453.HKD","PPH","BK4588","LU2272731865.HKD","LU2322448791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969921","title":"RBC Capital上调福泰制药目标价至570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969921","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649969921?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:24","pubTimestamp":1783499090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2417539215.USD","VRTX","LU1778281490.HKD","IE00B2B36J28.USD","LU0029864427.USD","UDN","LU1093756168.USD","BK4567","SG9999001176.USD","BIB","BK4207","IE00B894F039.SGD","SGXZ57979304.SGD","BK4532","LU2456880835.USD","LU0708994859.HKD","IDNA","IE0009355771.USD","BK4139","LU0128525929.USD","RY","LU1069344957.HKD","LU0320765992.SGD","LU2462157665.USD","LU0823416689.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0234570918.USD","IE00B4R5TH58.HKD","LU1267930573.SGD","PBE","LU0417517546.SGD","LU2324357040.USD","LU0058720904.USD","UUP","SG9999013999.USD","BBH","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","BK4533","GSIB","IBBQ","IE00B19Z9P08.USD","LU1093756325.SGD","LU2237438978.USD","LU2362540622.SGD","LU0310800379.SGD","IBB","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"(活力中国调研行)上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649952006?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’,上海团队有180多名全职员工,90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷,这片曾经的农田已崛起为世界级生物医药创新高地,而活跃其中的青年人才,正成为推动创新药研发的主力军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","SBIO","BK4581","161726","GDOC","LFSC","GSKH","BK4585","XBI","PBE","BBP","BK4588","WRND","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111378876","title":"Vera Therapeutics股价飙升:肾病新药获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1111378876","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111378876?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:47","pubTimestamp":1783450047,"startTime":"0","endTime":"0","summary":"周二,Vera Therapeutics, Inc.的股价上涨约8%,此前美国食品药品监督管理局批准了其用于治疗IgA肾病的药物。这款名为Trutakna的药物通过阻断两种蛋白质来发挥作用,这两种蛋白质会促使免疫系统产生抗体,这些抗体在肾脏中积聚并造成损伤。这是美国首个获批同时靶向这两种蛋白质的药物,尽管已有其他几种药物治疗该疾病。福泰制药正在研发一种同样能阻断这两种蛋白质的类似药物,FDA预计将在今年晚些时候对此做出裁决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2417539215.USD","LU0432979614.USD","LABU","LU2456880835.USD","SG9999001176.SGD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU2362540622.SGD","IE0002270589.USD","LU2462157665.USD","BK4532","IE00BJT1NW94.SGD","LU1674673428.USD","IE00BFTCPJ56.SGD","IBBQ","LU0320765992.SGD","IE00BJJMRZ35.SGD","IDNA","IE00B2B36J28.USD","SG9999013999.USD","BK4539","LU1093756168.USD","LU2362541513.USD","IE00BZ9MQY76.HKD","LU0256863811.USD","LU2237438978.USD","BK4585","BBH","BK4139","LU1093756325.SGD","LU1430594728.SGD","LU0823416689.USD","BK4533","BIB","LU2324357040.USD","BK4588","IE00B4R5TH58.HKD","LU0079474960.USD","LU0058720904.USD","IE00B19Z9Z06.USD","IE0002141913.USD","IE00B19Z3581.USD","LU0417517546.SGD","LU0289739699.SGD","SG9999001176.USD","LU1778281490.HKD","LU0061475181.USD","PBE","LU1069344957.HKD","LU1674673691.USD","LU1585245621.USD","LU2236285917.USD","SGXZ57979304.SGD","VRTX","LU0889565916.HKD","VERA","LU0109394709.USD","IE0009355771.USD","LU0234570918.USD","IBB","LU1035775433.USD","BK4567","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649984355?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰思艾泰-B 发布公告,为充分发挥产学研结合的优势,加速生物医药研发创新,公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台,以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知,围绕抗体发现与分子设计展开深度合作,共同打造新一代AI驱动的创新药研发范式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","BK4588","BBP","IBB","GSKH","LFSC","BK1535","VTHR","AIPO","03378","BK1161","GDOC","AGIX","ARTY","CHAT","PBE","BK4585","SBIO","WRND","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649708736","title":"100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2649708736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649708736?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:35","pubTimestamp":1783384535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0058720904.USD","IE00B19Z9Z06.USD","IBB","LU1778281490.HKD","LU2362541273.HKD","BIB","LU2456880835.USD","LU0823416689.USD","BK4533","LU0061475181.USD","BK4139","LU1035775433.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU2324357040.USD","SG9999001176.SGD","LU0417517546.SGD","VRTX","LU0079474960.USD","IE00B19Z9P08.USD","LU0320765992.SGD","BK4007","LU0109394709.USD","LU0234570918.USD","LU1585245621.USD","BK4588","LU1093756168.USD","LU1674673691.USD","LU0256863811.USD","LU0889565916.HKD","SG9999001176.USD","LU0289739699.SGD","BK4585","BBH","LU0432979614.USD","IE00B2B36J28.USD","CRNX","LU1430594728.SGD","IBBQ","SGXZ57979304.SGD","IDNA","IE00BZ9MQY76.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU2362540622.SGD","LU2417539215.USD","LU2237438978.USD","IE0002270589.USD","PBE","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159544198","title":"SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费","url":"https://stock-news.laohu8.com/highlight/detail?id=1159544198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159544198?lang=zh_cn&edition=full","pubTime":"2026-07-07 05:22","pubTimestamp":1783372928,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露,Crinetics Pharmaceuticals Inc. 与福泰制药之间的交易若在特定情况下被终止,前者可能需要向后者支付高达3.5047亿美元的终止费用。该文件明确了触发这一巨额财务义务的具体情形。协议条款显示,这笔费用的支付并非自动生效,而是与特定的终止条件紧密挂钩。然而,这也同时意味着,一旦协议因规定情形破裂,Crinetics Pharmaceuticals将面临显著的财务支出。目前,市场正密切关注两家公司后续的动向以及该交易的具体进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","IE0002270589.USD","BBH","LU1430594728.SGD","LU0256863811.USD","LU0079474960.USD","IBB","LU2237438978.USD","IE00B19Z9P08.USD","IE0002141913.USD","SG9999001176.USD","IE00BJT1NW94.SGD","BK4588","BK4532","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU1069344957.HKD","LU2362540622.SGD","LU1035775433.USD","LU0234570918.USD","LU0320765992.SGD","IBBQ","IE0009355771.USD","BIB","LU1674673691.USD","IE00BJJMRZ35.SGD","BK4139","LU0889565916.HKD","LU2456880835.USD","LU1674673428.USD","IE00B2B36J28.USD","LU1093756168.USD","IE00B19Z3B42.SGD","IE00B894F039.SGD","CRNX","LU0058720904.USD","LU0432979614.USD","LU0061475181.USD","LU2324357040.USD","SGXZ57979304.SGD","LU2462157665.USD","SG9999013999.USD","IDNA","LU2417539215.USD","LU0109394709.USD","BK4585","IE00B19Z3581.USD","LU0289739699.SGD","LU1093756325.SGD","LU1585245621.USD","LU2362541513.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","LU2236285917.USD","PBE","BK4533","LU0823416689.USD","LU1778281490.HKD","SG9999001176.SGD","VRTX","IE00B4R5TH58.HKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679149","title":"生物制药公司Crinetics盘后涨超100%福泰制药将以85美元/股收购公司。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649679149?lang=zh_cn&edition=full","pubTime":"2026-07-07 04:09","pubTimestamp":1783368555,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU1035775433.USD","PBE","IE00B19Z3581.USD","LU1093756325.SGD","UDN","LU1674673428.USD","LU2236285917.USD","SG9999001176.USD","LU2237438978.USD","IDNA","LU0079474960.USD","BK4532","IE00B19Z9Z06.USD","BBH","BK4567","BK4139","IBBQ","BK4588","LU0823416689.USD","MRNY","IE00B2B36J28.USD","SGXZ57979304.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","BK4533","LU1674673691.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","UUP","LU2362541513.USD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1585245621.USD","LU2362541273.HKD","IE00BJJMRZ35.SGD","IBB","LU2324357040.USD","IE00B19Z9P08.USD","MRNX","BIB","VRTX","LU0320765992.SGD","LU1778281490.HKD","IE0002141913.USD","LU2417539215.USD","LU2456880835.USD","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127833937","title":"Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1127833937","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127833937?lang=zh_cn&edition=full","pubTime":"2026-07-07 04:07","pubTimestamp":1783368452,"startTime":"0","endTime":"0","summary":"根据最新披露的财务预测,Crinetics Pharmaceuticals Inc. 与福泰制药达成的战略合作,预计将在2029年对福泰制药的非通用会计准则运营收入产生积极贡献。\n此次交易的结构设计旨在通过长期协同效应,增强福泰制药的盈利质量。分析指出,该合作不仅将拓展福泰制药在特定治疗领域的产品管线,还可能优化其整体运营效率。市场预期,随着合作项目进入成熟阶段,其对财务指标的正面影响将逐步显现。\n财务模型显示,此次合作带来的收入增长与成本协同效应,是推动非通用会计准则运营收入提升的关键因素。投资者正密切关注交易细节及后续整合进程,以评估其长期价值创造潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","IE0002141913.USD","LU1585245621.USD","IE00B19Z9Z06.USD","LU0823416689.USD","SG9999001176.SGD","LU1674673428.USD","LU0289739699.SGD","LU2362541273.HKD","IE00B19Z3581.USD","CRNX","LU2324357040.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0058720904.USD","BK4588","BBH","LU1069344957.HKD","LU1778281490.HKD","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4533","LU1430594728.SGD","LU0061475181.USD","VRTX","PBE","LU1093756325.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","IDNA","IE00BZ9MQY76.HKD","LU1093756168.USD","LU0320765992.SGD","IBBQ","BK4585","IE00B19Z9P08.USD","LU2236285917.USD","LU2362540622.SGD","LU2362541513.USD","IBB","LU1035775433.USD","LU2456880835.USD","BK4567","IE00B4R5TH58.HKD","LU0417517546.SGD","LU0432979614.USD","IE00B894F039.SGD","LU2462157665.USD","SG9999001176.USD","BK4532","IE0009355771.USD","SG9999013999.USD","LU0256863811.USD","BIB","LU0234570918.USD","BK4139","IE00BFTCPJ56.SGD","IE0002270589.USD","BK4007","LU2417539215.USD","LU1674673691.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179291339","title":"Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1179291339","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179291339?lang=zh_cn&edition=full","pubTime":"2026-07-07 04:06","pubTimestamp":1783368378,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. 的融资计划,已获得来自美国银行和摩根士丹利高级融资部门提供的总额高达45亿美元的全额承诺过桥贷款支持。这笔资金将为公司的战略推进提供坚实的财务后盾。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU1674673428.USD","BK4533","LU2362540622.SGD","LU1430594728.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","LU0432979614.USD","LU2462157665.USD","LU2362541513.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","IBB","IE00BZ9MQY76.HKD","IBBQ","SG9999001176.USD","LU1093756168.USD","IE0009355771.USD","LU0079474960.USD","LU1093756325.SGD","LU2236285917.USD","SG9999013999.USD","BK4585","SGXZ57979304.SGD","BK4007","LU0058720904.USD","BK4588","BBH","LU2456880835.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","BK4139","LU0417517546.SGD","LU0289739699.SGD","PBE","IE0002141913.USD","CRNX","IE0002270589.USD","IE00B894F039.SGD","LU0061475181.USD","LU0889565916.HKD","LU1778281490.HKD","LU2362541273.HKD","BK4532","LU1585245621.USD","LU2417539215.USD","LU1674673691.USD","BIB","BK4567","LU1035775433.USD","LU0256863811.USD","VRTX","LU0109394709.USD","IDNA","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154393441","title":"福泰制药就囊性纤维化疗法Alyftrek与泛加拿大药品联盟签署意向书","url":"https://stock-news.laohu8.com/highlight/detail?id=1154393441","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154393441?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:25","pubTimestamp":1783347947,"startTime":"0","endTime":"0","summary":"福泰制药与泛加拿大药品联盟就囊性纤维化治疗药物Alyftrek的潜在合作签署了意向书。此举标志着该药物在加拿大市场准入进程中的一个重要步骤,旨在为患者提供新的治疗选择。意向书的签署为后续正式协议的谈判奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0061475181.USD","BK4139","SGXZ57979304.SGD","BK4588","BIB","SG9999001176.SGD","IE00B2B36J28.USD","BK4533","IBB","LU0109394709.USD","LU0234570918.USD","LU1035775433.USD","LU0058720904.USD","LU1778281490.HKD","LU1093756168.USD","LU0823416689.USD","IE00B19Z9Z06.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0889565916.HKD","SG9999013999.USD","LU0289739699.SGD","LU2456880835.USD","LU1069344957.HKD","LU0079474960.USD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU2362541513.USD","SG9999001176.USD","LU0320765992.SGD","LU2462157665.USD","IE00B894F039.SGD","IE0009355771.USD","LU2362540622.SGD","BBH","BK4567","IE00BJT1NW94.SGD","LU0417517546.SGD","LU1585245621.USD","IE00B19Z9P08.USD","LU2237438978.USD","LU2417539215.USD","LU2236285917.USD","IBBQ","IE00B19Z3581.USD","LU1430594728.SGD","PBE","BK4585","LU1674673691.USD","LU0432979614.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0256863811.USD","LU1674673428.USD","LU2324357040.USD","BK4532","VRTX","IDNA","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132494711","title":"再生元制药公司预计2026年第二季度GAAP及非GAAP每股摊薄收益将减少1美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1132494711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132494711?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:03","pubTimestamp":1783335796,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件,再生元制药公司(Regeneron Pharmaceuticals)预计,其2026年第二季度的美国通用会计准则(GAAP)及非美国通用会计准则(Non-GAAP)每股摊薄收益将出现下降,减少幅度约为1美元。这一预期反映了公司在特定时期内的财务表现可能面临的调整或挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2089984988.USD","LU2468319806.SGD","LU0114720955.EUR","LU2362540622.SGD","LU0053666078.USD","LU1917777945.USD","LU0823434740.USD","LU0320765992.SGD","IBBQ","LU2362541513.USD","LU0882574055.USD","BK4585","LU2237438978.USD","BBH","BK4139","LU0823416689.USD","REGN","BK4588","LU2106854487.HKD","LU1974910355.USD","LU0058720904.USD","LU0823434583.USD","LU0289739699.SGD","LU0889565916.HKD","LU0109394709.USD","IBB","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142675479","title":"礼来与再生元制药公司入选FDA首批加速新生产设施审查计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1142675479","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142675479?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:15","pubTimestamp":1783322114,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)近日启动了一项旨在加速新生产设施审查的倡议,而制药巨头礼来与再生元制药公司成为首批入选该计划的企业。此举旨在通过优化监管流程,缩短创新药物生产设施从建设到获批投产的时间,从而更快地将关键疗法推向市场。\n对于礼来和再生元而言,参与此计划意味着其未来新建或扩建的生产基地可能获得FDA更优先、更高效的审查。在当前全球生物制药竞争日益激烈的背景下,提升产能布局的敏捷性至关重要,尤其是在糖尿病、肥胖症、癌症及炎症性疾病等需求旺盛的治疗领域。这一监管合作模式有望成为行业加速发展的新催化剂。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU1974910355.USD","LU0823416689.USD","LU1267930730.SGD","IE00BKDWB100.SGD","LU0320765059.SGD","LU1629891620.HKD","LU1551013425.SGD","LU1093756325.SGD","LU2756315318.SGD","LU2265009873.SGD","LU2471134523.USD","IE00BJJMRY28.SGD","LU0354030511.USD","LLYX","SG9999014914.USD","LU2746668461.USD","THNR","LU0640476718.USD","LU2023250330.USD","IBBQ","IE00B1BXHZ80.USD","LLII","LU2362541513.USD","SG9999015986.USD","IXJ","LU0061475181.USD","LU0345770993.USD","LU2211815571.USD","LU1868836591.USD","LU2552382058.USD","LU2028103732.USD","OZEM","LU1548497426.USD","LU0466842654.USD","BK4139","LU2417539215.USD","IE0004445239.USD","LU0417517546.SGD","IE00BK4W5L77.USD","LU1291159041.SGD","LU0786609619.USD","LU2552382215.SGD","LU2360106947.USD","LU2750360641.GBP","SG9999001176.SGD","IYH","LU0198837287.USD","LU1720051017.SGD","IE0001KFT4U8.USD","BK4516","LU0471298694.HKD","LU2264538146.SGD","IE00BJJMRZ35.SGD","LU2108987350.USD","LU1983299246.USD","LU0672654240.SGD","SG9999014898.SGD","LU1366192091.USD","LU0820562030.AUD","LU0708995401.HKD","LU0094547139.USD","LU0109391861.USD","LU2168564495.EUR","PPH","IE00B1XK9C88.USD","LU0889565916.HKD","LU1989771016.USD","GDOC","IE00B4JS1V06.HKD","SGXZ57979304.SGD","HRTS","PJP","IE0004445015.USD","IE00B2B36J28.USD","LU0106261372.USD","LU0203201768.USD","LU2237438978.USD","LU2063271972.USD","ELIL","LU2361044865.SGD","BK4581","LU1623119135.USD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU0225283273.USD","LU2237443978.SGD","LU1035775433.USD","LU0238689110.USD","CURE","LU2213496289.HKD","LU2236285917.USD","BK4534","IE00BFSS8Q28.SGD","LU1061106388.HKD","LU0787776722.HKD","SG9999018857.SGD","LU0256863811.USD","LLYZ","LU1093756168.USD","LU0058720904.USD","LU0158827948.USD","LU1988902786.USD","LU2456880835.USD","LU0385154629.USD","SG9999014880.SGD","LU1720051108.HKD","LU1057294990.SGD","IE00BFSS7M15.SGD","LU2237443549.SGD","LU1232071149.USD","LU1868837136.USD","SGXZ81514606.USD","LU0097036916.USD","ILDR","MEDI","LU2237443622.USD","LU0316494557.USD","LU2361044949.HKD","LU0432979614.USD","FTXH","LU0683600562.USD","LU1868836914.USD","BBH","LU2324357040.USD","LU0471298777.SGD","LU0354030438.USD","SG9999013999.USD","LU2746668974.SGD","LU1814569148.SGD","LU2362541273.HKD","LU2087625088.SGD","LU2491050071.SGD","LU1280957306.USD","LU0114720955.EUR","LU1069344957.HKD","SGXZ51526630.SGD","LU2237443895.HKD","LU0053666078.USD","LU1712237335.SGD","LU1868836757.USD","LU0289739699.SGD","FHLC","IE00BWXC8680.SGD","LU0256863902.USD","LU2237443465.HKD","LU2750360997.AUD","CANC","LU0323591593.USD","LU1127390331.HKD","LU1145028129.USD","LU0203202063.USD","IHE","IE00BKPKM429.USD","LLY","LU1023059063.AUD","LU2112291526.USD","LU2471134952.CNY","IBB","LU0234572021.USD","BK4599","IE00BJLML261.HKD","IE00B7KXQ091.USD","SG9999015945.SGD","LU0320765992.SGD","LU2168564065.EUR","LU2168564149.EUR","SG9999014906.USD","LU2491049909.HKD","LU2756315664.SGD","JDOC","LU0823434583.USD","LU2361045086.USD","LU0266013472.USD","LU2471134796.USD","BK4007","LU1551013342.USD","BK4533","LU2023250504.SGD","LU2111349929.HKD","LU2106854487.HKD","LU2461242641.AUD","BK4585","IE00BN29S564.USD","LU0882574055.USD","LU1917777945.USD","LU2168563687.JPY","IE00BJT1NW94.SGD","LU2896262040.SGD","VHT","GB00BDT5M118.USD","LU2462157665.USD","IE0005OL40V9.USD","LU0820561818.USD","LU0353189763.USD","LU2023251221.USD","LU0456855351.SGD","LU2271345857.HKD","LU2089283258.USD","REGN","SG9999015978.USD","IE00B775H168.HKD","LU1064131342.USD","LU0820561909.HKD","SG9999018865.SGD","SGXZ31699556.SGD","LU0006306889.USD","SGXZ99366536.SGD","LU2491050154.USD","IE00BK4W5M84.HKD","LU0122379950.USD","LU2362540622.SGD","LU2602419157.SGD","LU2468319806.SGD","LU2089984988.USD","LU2471134879.HKD","LU0133085943.USD","LU0943347566.SGD","LU1323610961.USD","LU0353189680.USD","LU2237443382.USD","WDNA","LU0158827781.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0345770308.USD","LU0964807845.USD","ELIS","IE0009355771.USD","SG9999001176.USD","LU0823434740.USD","LU1804176565.USD","LU2168564222.USD","LU2357305700.SGD","LU1868837300.USD","LU0689472784.USD","IE00BJJMRX11.SGD","LU0096364046.USD","LU2089284900.SGD","LU2552382132.HKD","LU0210536198.USD","AGNG","LU0109394709.USD","MEDX","RXL","SG9999017495.SGD","XLV","BK4588","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112712189","title":"ETF日报|2倍做空闪迪ETF 涨逾28%;三倍做空半导体ETF 涨近17%;成长承压、贵金属走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1112712189","media":"ETF追踪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112712189?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:42","pubTimestamp":1783039362,"startTime":"0","endTime":"0","summary":"2倍做多AVAV ETF-Defiance上涨21.55%。美股ETF跌幅Top5Corgi ACLS 2x Daily ETF下跌37.68%。大盘指数ETF涨幅Top 5纳指三倍做空ETF上涨5.46%。大宗商品ETF涨幅Top 5二倍做多黄金矿业指数ETF-Direxion上涨8.61%。2倍做多黄金ETF-ProShares上涨4.08%。行业指数ETF涨幅Top 5三倍做空半导体ETF-Direxion Daily上涨16.84%。该产品三倍做空半导体板块,板块回落令反向产品大幅走高。债券ETF涨幅Top 5Infracap REIT Preferred ETF上涨1.20%。总结当日ETF结构显示科技成长承压,半导体多头显著回撤,做空半导体与做空纳斯达克100指数产品领涨。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2482c489456454bb2227ec34bbeb7d8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFFR","EWG","AEHG","SNDQ","GDX","EMLC","NUGT","UYM","GDXJ","VRP","APPC","AVXX","QID","IREZ","DRN","FAS","UDOW","IBB","MRNX","AGQ","UCTX","SQQQ","LEMB","ACLZ","UGL","EBND","ACMM","EWU","SOXS","FOMG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1153818821","title":"ETF日报|2倍做多Firefly Aerospace ETF涨超36%;2倍做多Arm ETF涨超32%;成长科技与贵金属双强","url":"https://stock-news.laohu8.com/highlight/detail?id=1153818821","media":"ETF追踪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153818821?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:25","pubTimestamp":1774491900,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多SRPT ETF-Tradr$上涨69.23%。Sarepta Therapeutics周三大涨近35%,此前该公司公布了两项治疗罕见肌肉萎缩症的初步数据。该产品两倍做多航空航天公司$Firefly Aerospace$,标的股价上行带动产品大幅走高,杠杆效应放大收益。有报道称埃隆马斯克旗下的SpaceX最快将于本周提交上市申请,周三太空概念股应声飙升,Firefly Aerospace涨超16%,Intuitive Machines涨近15%,Planet Labs涨超11%,Rocket Lab和AST SpaceMobile涨超10%。$2倍做多ARM ETF- Leverage Shares$上涨32.51%。$罗素2000指数三倍做多ETF-Direxion$上涨3.63%。债券ETF涨幅Top 5$Infracap REIT Preferred ETF$上涨1.33%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDC","AMD","PL","PFFR","AGQ","SRPT","PLU","SMCI","PCY","ASTS","IBB","DKNG","UGL","ARM","SLV","XPP","TLT","DKNX","RKLZ","ARMG","TNA","SRPU","FLY","NUGT","DAMD","TAN","LUNL","DGP","SOXL","FLYT","SMCZ","SPTL","LUNR","NLR","CHAU","EMB","UYM","RKLB","YINN","ASTN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177597123","title":"ETF日报|2倍做多Hims & Hers ETF涨超81%;三倍做多半导体ETF涨超11%;成长风格领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177597123","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177597123?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:30","pubTimestamp":1773109800,"startTime":"0","endTime":"0","summary":"大宗商品中,白银相关ETF显著走强,原油做多品种回落。该产品两倍做多在线医疗平台公司$Hims & Hers Health$,因底层公司股价上涨,杠杆机制放大当日涨幅。$诺和诺德$计划在Hims & Hers Health平台销售减重药物,双方结束此前的法律纠纷,公司股价大幅上涨。该产品围绕Hims & Hers Health开展期权收益策略,因公司股价上行,份额净值同步走高。$2倍做多恐慌指数期货ETF$下跌19.40%。行业指数ETF涨幅Top 5$三倍做多半导体ETF-Direxion Daily$上涨11.34%。债券ETF涨幅Top 5$First Trust SSI Strategic Convertible Securities ETF$上涨2.02%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823414478.USD","BK4585","LU2264538146.SGD","SMH","LU1815336760.USD","HIMS","LU0444973449.USD","XLK","LU2294711713.HKD","LU2249611893.SGD","RDW","BK4182","CRCD","EDC","AGQ","CRCL","FCVT","LU1064131342.USD","LU2543165471.USD","RDWU","SPLB","LU1642822529.SGD","BK4588","YINN","CWB","IBB","BEG","TQQQ","SLV","BEZ","EWY","LU0476273544.USD","BK4541","LU0957808578.USD","LU2357125470.USD","NUGT","VCLT","OIH","LU0444971666.USD","LU1988902786.USD","BMNR","RCAX","LU2506951792.HKD","BK4550","HIYY","BMNZ","ICVT","BE","TUR","UVIX","LU0823414551.USD","SOXL","HIMZ","LITX","NLR","LITE","DGZ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174260286","title":"ETF追踪 | 生物科技ETF:在经济不确定中把握增长和防御机会","url":"https://stock-news.laohu8.com/highlight/detail?id=1174260286","media":"ETF小帮手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174260286?lang=zh_cn&edition=full","pubTime":"2024-10-30 14:18","pubTimestamp":1730269129,"startTime":"0","endTime":"0","summary":"由于药品审批加速、并购活动频繁,以及人工智能在药物发现中的应用不断取得突破,顶级生物科技ETF在2024年表现相当不错,成为投资者关注的热点。当前市场环境下的生物科技ETF前景在目前的市场环境中,生物科技ETF的前景受到多重因素影响。结论生物科技ETF提供了一个兼具成长性和创新性的投资机会。通过选择不同的ETF,投资者可以灵活参与生物科技行业的不同细分领域,达到风险分散和增长潜力的平衡。","market":"sh","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPY","BBC","BK4550","ARKG","IBB","BK4585","DJX","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0327},{"period":"1month","weight":0.1763},{"period":"3month","weight":0.1405},{"period":"6month","weight":0.1389},{"period":"1year","weight":0.5181},{"period":"ytd","weight":0.1634}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。\n风险提示:标的成分和权重,有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.722222,"avgChangeRate":0.019108},{"month":2,"riseRate":0.611111,"avgChangeRate":-0.001245},{"month":3,"riseRate":0.555556,"avgChangeRate":0.002788},{"month":4,"riseRate":0.5,"avgChangeRate":0.003638},{"month":5,"riseRate":0.611111,"avgChangeRate":0.009102},{"month":6,"riseRate":0.777778,"avgChangeRate":0.027534},{"month":7,"riseRate":0.777778,"avgChangeRate":0.038551},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.000694},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.000938},{"month":10,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":11,"riseRate":0.833333,"avgChangeRate":0.040881},{"month":12,"riseRate":0.555556,"avgChangeRate":0.007272}],"exchange":"NASDAQ","name":"生物科技指数ETF-iShares Nasdaq","nameEN":"iShares Biotechnology ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技指数ETF-iShares Nasdaq,IBB,生物科技指数ETF-iShares Nasdaq股票,生物科技指数ETF-iShares Nasdaq股票老虎,生物科技指数ETF-iShares Nasdaq股票老虎国际,生物科技指数ETF-iShares Nasdaq行情,生物科技指数ETF-iShares Nasdaq股票行情,生物科技指数ETF-iShares Nasdaq股价,生物科技指数ETF-iShares Nasdaq股市,生物科技指数ETF-iShares Nasdaq股票价格,生物科技指数ETF-iShares Nasdaq股票交易,生物科技指数ETF-iShares Nasdaq股票购买,生物科技指数ETF-iShares Nasdaq股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}